Search results
Showing 346 to 360 of 1286 results for long term conditions
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Evidence-based recommendations on using coronary artery stents in adults.
Kidney conditions: CKD and blood pressure when ACR 70 or more (IND264)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 125/75 mmHg if using ambulatory or home monitoring, or less than 130/80 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM248.
This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual